Biodesix FCF par action

Que fait Biodesix ? Biodesix, Inc. generates revenue through blood-based diagnostic testing services for lung disease patients, including Nodify XL2, Nodify CDT, GeneStrat, and VeriStrat tests. The company also provides SARS-CoV-2 testing services under the Biodesix WorkSafe program, utilizing Bio-Rad SARS-CoV-2 ddPCR, Platelia SARS-CoV-2 Total Ab, and cPass SARS-CoV-2 Neutralizing Antibody tests. Biodesix serves biopharmaceutical companies with diagnostic research, clinical research, development, and testing services, as well as companion diagnostics development and commercialization, all governed by individual contracts with third parties. The primary customers for Biodesix's diagnostic services are patients with lung disease and biopharmaceutical companies seeking specialized testing solutions. The company's artificial intelligence platform supports the discovery and development of clinical solutions for unmet needs in lung disease, enhancing the value of its blood-based tests. Biodesix's focus on lung disease diagnostics and SARS-CoV-2 testing positions it to serve both healthcare providers and pharmaceutical partners in the biotechnology sector. Biodesix's revenue streams include direct patient testing services, SARS-CoV-2 testing programs, and contract-based services for biopharmaceutical companies. The company's blood-based lung cancer tests and SARS-CoV-2 testing options are sold through specific product names and programs, with no mention of additional pricing or subscription models. The business model relies on contractual agreements for services provided outside clinical settings, emphasizing tailored diagnostic solutions for lung disease and infectious disease testing. Biodesix est l'une des entreprises les plus populaires sur Eulerpool.